GRIFFIN; James Douglas

Patent Applications and Registrations

Patent applications and USPTO patent grants for GRIFFIN; James Douglas.The latest application filed is for "compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators".

Company Profile

2.7.20

GRIFFIN; James Douglas - Brookline MA US
Griffin; James Douglas - Boston MA US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compositions And Methods For Identification, Assessment, Prevention, And Treatment Of Aml Using Usp10 Biomarkers And Modulators App 20190202929 - Buhrlage; Sara ; et al.	2019-07-04
Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias App 20170209458 - Griffin; James Douglas ; et al.	2017-07-27
Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias Grant 9,700,565 - Griffin , et al. July 11, 2	2017-07-11
Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias App 20160184319 - Griffin; James Douglas ; et al.	2016-06-30
Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias App 20140303146 - Griffin; James Douglas ; et al.	2014-10-09
Method Of Treating Mixed Lineage Leukemia Gene-rearranged Acute Lymphoblastic Leukemias App 20140057897 - Griffin; James Douglas ; et al.	2014-02-27
Combination of IAP inhibitors and FLT3 inhibitors Grant 8,492,429 - Griffin , et al. July 23, 2	2013-07-23
Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity Grant 8,445,479 - Griffin , et al. May 21, 2	2013-05-21
Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias App 20120329779 - Griffin; James Douglas ; et al.	2012-12-27
Staurosporine Derivatives As Inhibitors Of Flt3 Receptor Tyrosine Kinase Activity App 20120252785 - GRIFFIN; James Douglas ; et al.	2012-10-04
Staurosporine Derivatives as Inhibitors of FLT3 Receptor Tyrosine Kinase Activity App 20110224194 - Griffin; James Douglas ; et al.	2011-09-15
Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity Grant 7,973,031 - Griffin , et al. July 5, 2	2011-07-05
Method Of Treating Mixed Lineage Leukemia Gene-rearranged Acute Lymphoblastic Leukemias App 20110009383 - GRIFFIN; James Douglas ; et al.	2011-01-13
Combination Of Iap Inhibitors And Flt3 Inhibitors App 20100056467 - Griffin; James Douglas ; et al.	2010-03-04
Use of Staurosporine Derivatives for the Treatment of Multiple Myeloma App 20090286770 - Gilliland; D. Gary ; et al.	2009-11-19
Epothilone Derivatives For The Treatment Of Multiple Myeloma App 20090233973 - Lin; Boris ; et al.	2009-09-17
Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias App 20080221080 - Griffin; James Douglas ; et al.	2008-09-11
Staurosporine derivatives for hypereosinophilic syndrome App 20060229290 - Gilliland; D. Gary ; et al.	2006-10-12
Epothilone derivatives for the treatment of multiple myeloma App 20060094766 - Lin; Boris ; et al.	2006-05-04
Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity App 20050020570 - Griffin, James Douglas ; et al.	2005-01-27

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.